Nakahashi Kenta, Nakatsuka Marina, Endo Makoto, Shiono Satoshi
Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Faculty of Medicine, Second Department of Surgery, Yamagata University, Yamagata, Japan.
J Thorac Dis. 2023 Jul 31;15(7):3849-3859. doi: 10.21037/jtd-23-292. Epub 2023 Jul 17.
Tumor volume doubling time (VDT) has been shown to predict prognosis in various non-small cell lung carcinoma with scant evidence for lung squamous cell carcinoma (SCC). The purpose of this study was to investigate the prognostic value of tumor VDT in resected lung SCCs.
In this study, subjects were 51 patients who underwent lobectomy for clinical stage I SCC of the peripheral lung at our institution between January 2006 and April 2020. Univariable and multivariable analyses of overall survival (OS) and recurrence-free survival (RFS) were performed using the Cox proportional hazards model. The Kaplan-Meier method was used to create OS and RFS curves and to determine statistical significance. The cut-off value of VDT was defined by receiver operating characteristic (ROC) curve analysis on survival.
Multivariable analysis found only VDT (HR, 0.990; 95% CI: 0.979-0.997) to be an independent predictor of OS. Also, only VDT (HR, 0.989; 95% CI: 0.978-0.995) was an independent predictor of RFS. The 5-year OS rates were 88.4% and 30.4% in the long (≥150 days) and short (<150 days) VDT groups, respectively (P=0.002). The 5-year RFS rates were 88.8% and 26.5% in the long (≥150 days) and short (<150 days) VDT groups, respectively (P<0.001).
Tumor VDT was found to be a useful prognostic predictor in clinical stage I lung SCC in this study.
肿瘤体积倍增时间(VDT)已被证明可预测各种非小细胞肺癌的预后,但肺鳞状细胞癌(SCC)的相关证据较少。本研究旨在探讨肿瘤VDT在肺SCC切除术后的预后价值。
本研究纳入了2006年1月至2020年4月期间在我院接受肺叶切除术的51例临床I期周围型肺SCC患者。采用Cox比例风险模型对总生存期(OS)和无复发生存期(RFS)进行单因素和多因素分析。采用Kaplan-Meier法绘制OS和RFS曲线并确定统计学意义。通过生存的受试者工作特征(ROC)曲线分析确定VDT的临界值。
多因素分析发现,只有VDT(HR,0.990;95%CI:0.979-0.997)是OS的独立预测因素。此外,只有VDT(HR,0.989;95%CI:0.978-0.995)是RFS的独立预测因素(HR,0.989;95%CI:0.978-0.995)。长VDT组(≥150天)和短VDT组(<150天)的5年OS率分别为88.4%和30.4%(P=0.002)。长VDT组(≥150天)和短VDT组(<150天)的5年RFS率分别为88.8%和26.5%(P<0.001)。
本研究发现肿瘤VDT是临床I期肺SCC的有用预后预测指标。